Maia Kayal

Dr. Maia Kayal

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PDF file
SRSheila D. Rustgi
Sheila D. Rustgi
MKMaia Kayal
Maia Kayal
SSShailja Shah
Shailja Shah
Sex-based differences in inflammatory bowel disease (IBD) pathogenesis, disease course, and response to therapy have been increasingly recognized, however, not fully understood. Experimental and translational models have been leveraged to investigate hypothesized mechanisms for these observed differences, including the potential modifying role of sex hormones and sex-dependent (epi)genetic and gut microbiome changes. The primary objective of this review is to comprehensively describe sex-based differences in IBD including epidemiology, pathogenesis, phenotypic differences, therapeutic response, and outcomes.

30 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMaia Kayal
Maia Kayal
SSShailja Shah
Shailja Shah
Historically, medical therapy for ulcerative colitis (UC) was limited to corticosteroids. Excitingly, over the past just 1–2 decades, the options for medical therapy have expanded and include biologics and small molecules, with more agents actively being developed. In this article, we review the current and emerging treatment strategies for UC stratified according to disease severity.

21 April 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MDMichael T Dolinger
Michael T Dolinger
MKMaia Kayal
Maia Kayal
Intestinal ultrasound as a non-invasive tool to monitor inflammatory bowel disease activity and guide clinical decision making

18 June 2020 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
MKMaia Kayal
Maia Kayal
MPMichael Plietz
Michael Plietz
ARAnam Rizvi
Anam Rizvi
MRMarlana Radcliffe
Marlana Radcliffe
ARAlexa Riggs
Alexa Riggs
MDMarla C Dubinsky
Marla C Dubinsky
Background: Total proctocolectomy (TPC) with ileal pouch anal anastomosis (IPAA) is the gold standard surgery for ulcerative colitis (UC) patients with medically refractory disease. The aim of this study was to report the rates and risk factors of inflammatory pouch conditions. Methods: This was a retrospective review of UC or IBD unspecified (IBDU) patients who underwent TPC with IPAA for refractory disease or dysplasia between 2008 and 2017. Pouchoscopy data were used to calculate rates of inflammatory pouch conditions. Factors associated with outcomes in univariable analysis were investigated in multivariable analysis. Results: Of the 621 patients more than 18 years of age who underwent TPC with IPAA between January 2008 and December 2017, pouchoscopy data were available for 386 patients during a median follow-up period of 4 years. Acute pouchitis occurred in 205 patients (53%), 60 of whom (30%) progressed to chronic pouchitis. Cuffitis and Crohn's disease–like condition (CDLC) of the pouch occurred in 119 (30%) patients and 46 (12%) patients, respectively. In multivariable analysis, female sex was associated with a decreased risk of acute pouchitis, and pre-operative steroid use and medically refractory disease were associated with an increased risk; IBDU was associated with chronic pouchitis; rectal cuff length ≥2 cm and medically refractory disease were associated with cuffitis; age 45–54 at colectomy was associated with CDLC. Rates of pouch failure were similar in chronic pouchitis and CDLC patients treated with biologics and those who were not. Conclusions: Inflammatory pouch conditions are common. Biologic use for chronic pouchitis and CDLC does not impact the rate of pouch failure.

1 March 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MKMaia Kayal
Maia Kayal
RURyan C. Ungaro
Ryan C. Ungaro
GBGeoffrey Bader
Geoffrey Bader
JCJean-Frederic Colombel
Jean-Frederic Colombel
WSWilliam J. Sandborn
William J. Sandborn
CSCarlos Stalgis
Carlos Stalgis

6 February 2023 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
SAShintaro Akiyama
Shintaro Akiyama
NCNathaniel A Cohen
Nathaniel A Cohen
MKMaia Kayal
Maia Kayal
MDMarla C Dubinsky
Marla C Dubinsky
JCJean-Frederic Colombel
Jean-Frederic Colombel
DRDavid T Rubin
David T Rubin
Approximately 10% to 15% of patients with ulcerative colitis (UC) undergo restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) due to medically refractory colitis or neoplasia.1 While IPAA is an excellent alternative to a permanent end ileostomy for patients with UC, up to 50% of patients develop acute pouchitis, and 10% to 15% of patients develop chronic pouch inflammation.1 Tofacitinib, a Janus kinase 1/3 inhibitor, has been approved for induction and maintenance of remission in patients with moderate to severe UC who failed anti-tumor necrosis factor agents.2 To date, 2 case reports showed that tofacitinib was effective for chronic pouchitis (CP)3 or Crohn’s disease–like pouch inflammation (CDLPI).4 On the other hand, a recent case series including 6 patients with CP, cuffitis, or CDLPI showed that 1 patient achieved clinical response, but all patients ultimately discontinued tofacitinib due to the lack of efficacy and adverse events.5 Therefore, data regarding its effectiveness are still controversial. This study aims to assess the effectiveness and safety of tofacitinib for patients with CP or CDLPI.